News
IPSEY
47.95
NaN%
--
Weekly Report: what happened at IPSEY last week (0420-0424)?
Weekly Report · 2d ago
Ipsen S.A. reports Q1 results; reaffirms FY outlook
Seeking Alpha · 6d ago
Here are the major earnings before the open Thursday
Seeking Alpha · 6d ago
Ipsen: European Commission Grants Conditional Marketing Authorization For Ojemda
NASDAQ · 04/22 06:56
Weekly Report: what happened at IPSEY last week (0413-0417)?
Weekly Report · 04/20 10:10
Weekly Report: what happened at IPSEY last week (0406-0410)?
Weekly Report · 04/13 10:13
Centessa is the top performing foreign healthcare stock YTD
Seeking Alpha · 04/08 21:43
Weekly Report: what happened at IPSEY last week (0330-0403)?
Weekly Report · 04/06 10:14
Weekly Report: what happened at IPSEY last week (0323-0327)?
Weekly Report · 03/30 10:14
Weekly Report: what happened at IPSEY last week (0316-0320)?
Weekly Report · 03/23 10:10
Ipsen Highlighted Early Immuno-Oncology Advances With New Data Presented At AACR
NASDAQ · 03/18 09:38
Weekly Report: what happened at IPSEY last week (0309-0313)?
Weekly Report · 03/16 10:10
Weekly Buzz: BMY Wins FDA Nod; EU Okays JNJ's AKEEGA; IPSEY Withdraws Tazverik, DAWN Acquired
NASDAQ · 03/13 14:14
Regeneron: Fairly Valued Now After A Stellar Upswing
Seeking Alpha · 03/11 13:47
Weekly Report: what happened at IPSEY last week (0302-0306)?
Weekly Report · 03/09 10:10
Ipsen Withdraws Tazverik Following Safety Concerns In SYMPHONY-1 Trial
NASDAQ · 03/09 07:46
EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug
NASDAQ · 03/06 15:02
Day One Biopharma to be acquired by Servier for $2.5B
Seeking Alpha · 03/06 14:07
Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth
Seeking Alpha · 03/05 19:41
Day One Biopharmaceuticals gains amid takeover speculation
Seeking Alpha · 03/04 18:04
More
Webull provides a variety of real-time IPSEY stock news. You can receive the latest news about Ipsen Sa through multiple platforms. This information may help you make smarter investment decisions.
About IPSEY
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.